netFormulary
 Report : Medicines with links to NICE 06/10/2024 00:27:20

[Back]

Report looks at the links table and pulls back all the items in the formulary where there is a link with 'nice.org' in the URL

You can sort this table Medicines Link Name or Link URL by clicking on the title

Selecting the Medicine name will take you to the entry in the formulary, Selecting the Link name will follow the link

 
Medicines/Item Section Status Link Name / Link URL
Abatacept 10.01.03 Formulary NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Abatacept 10.01.03 Formulary NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Abatacept 10.01.03 Formulary NICE TA715: Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed
Abrocitinib 13.05.03 Formulary NICE TA814: Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis
Adalimumab 10.01.03 Formulary NICE TA195:Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor
Adalimumab 10.01.03 Formulary NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Adalimumab 10.01.03 Formulary NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Adalimumab 10.01.03 Formulary NICE TA715: Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed
Adalimumab 10.01.03 Formulary NICE TA199: Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis
Adalimumab 10.01.03 Formulary NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Adalimumab 13.05.03 Formulary NICE TA392: Adalimumab for treating moderate to severe hidradenitis suppurativa
Adalimumab 13.05.03 Formulary NIE TA146: Adalimumab for the treatment of adults with psoriasis
Adalimumab 13.05.03 Formulary NICE TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
Adalimumab 01.05.03 Formulary NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
Adalimumab 01.05.03 Formulary NICE TA187: Infliximab and adalimumab for the treatment of Crohn’s disease
Adalimumab 01.05.03 Formulary NICE TA187: Infliximab and adalimumab for the treatment of Crohn’s disease
Adalimumab 11.10 Formulary NICE TA460: Adalimumab and dexamethasone for treating non-infectious uveitis
Adrenaline 03.04.03 Formulary NICE NG134: Anaphylaxis: assessment and referral after emergency treatment
Aflibercept 11.08.02 Formulary NICE TA: Aflibercept for treating diabetic macular oedema
Aflibercept 11.08.02 Formulary NICE TA486: Aflibercept for treating choroidal neovascularisation
Aflibercept 11.08.02 Formulary NICE TA409: Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion
Alirocumab 02.12 Formulary NICE TA393 - Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
Alitretinoin 13.05.01 Formulary NICE TA177: Alitretinoin for the treatment of severe chronic hand eczema
Alteplase 02.10.02 Formulary NICE TA52: Guidance on the use of drugs for early thrombolysis in the treatment of acute myocardial infarction
Alteplase 02.10.02 Formulary NICE TA264 - Alteplase for treating acute ischaemic stroke
Alteplase 02.10.02 Formulary NICE TA264: Ischaemic stroke (acute) - alteplase
Anakinra 10.01.03 Formulary NICE TA685: Anakinra for treating Still’s disease
Andexanet alfa 02.08.02 Formulary NICE TA697- Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban
Apixaban 02.08.02 Formulary NICE TA275: Apixaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation
Apixaban 02.08.02 Formulary NICE TA245: Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults
Apixaban 02.08.02 Formulary NICE TA341: Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
Apremilast 13.05.03 Formulary NICE TA419: Apremilast for treating moderate to severe plaque psoriasis
Apremilast 13.05.03 Formulary NICE TA433: Apremilast for treating active psoriatic arthritis
Apremilast 10.01.03 Formulary NICE TA433: Apremilast for treating active psoriatic arthritis
Aripiprazole 04.02.01 Formulary NICE TA213: Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years
Aripiprazole 04.02.01 Formulary NICE TA292: Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder
Asfotase alfa 09.08.01 Formulary NICE: Asfotase alfa for treating paediatric-onset hypophosphatasia
Ataluren 10.02 Formulary NICE:Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene
Atogepant 04.06 Formulary NICE TA973: Atogepant for preventing migraine
Avalglucosidase alfa 09.08.01 Formulary NICE TA821: Avalglucosidase alfa for treating Pompe disease
Avatrombopag 09.01.04 Formulary NICE TA626: Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure
Avatrombopag 09.01.04 Formulary NICE TA853: Avatrombopag for treating primary chronic immune thrombocytopenia
Baricitinib 10.01.03 Formulary NICE TA466: Baricitinib for moderate to severe rheumatoid arthritis
Baricitinib 13.05.03 Formulary NICE TA926: Baricitinib for treating severe alopecia areata
Baricitinib 13.05.03 Formulary NICE TA681: Baricitinib for treating moderate to severe atopic dermatitis
Belimumab 10.01 Formulary NICE TA806: Belimumab for treating lupus nephritis (terminated appraisal)
Belimumab 10.01 Formulary NICE TA752:Belimumab for treating active autoantibody-positive systemic lupus erythematosus
Bempedoic acid with Ezetimibe 02.12 Formulary NICE TA694 - Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia
Benralizumab 03.04.02 Formulary NICE TA565: Benralizumab for treating severe eosinophilic asthma
Berotralstat dihydrochloride 03.04.03 Formulary NICE TA738:Berotralstat for preventing recurrent attacks of hereditary angioedema
Bimekizumab 10.01.03 Formulary NICE TA918: Bimekizumab for treating axial spondyloarthritis
Bimekizumab 10.01.03 Formulary NICE TA916: Bimekizumab for treating active psoriatic arthritis
Bimekizumab 13.05.03 Formulary NICE TA723: Bimekizumab for treating moderate to severe plaque psoriasis
Birch bark extract 13.01 Formulary NICE: Birch bark extract for treating epidermolysis bullosa
Bivalirudin 02.08.01 Formulary NICE NG185: Acute coronary syndromes
Bivalirudin 02.08.01 Non Formulary NICE CG 94:Unstable angina and NSTEMI
Bivalirudin 02.08.01 Non Formulary NICE TAG 230 : Bivalirudin for the treatment of STEMI, 2011
Bosentan 02.05.01 Non Formulary NICE NG167: COVID-19 rapid guideline: rheumatological autoimmune, inflammatory and metabolic bone disorders
Bosentan 02.06.04 Formulary NICE NG167: COVID-19 rapid guideline: rheumatological autoimmune, inflammatory and metabolic bone disorders
Botulinum toxin type A 01.02 Formulary NICE TA605: Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea
Botulinum Toxin Type A 04.07.04.02 Formulary NICE TA260: Botulinum toxin type A for the prevention of headaches in adults with chronic migraine
Brodalumab 13.05.03 Formulary NICE TA511: Brodalumab for treating moderate to severe plaque psoriasis
Brolucizumab 11.08.02 Formulary NICE TA672: Brolucizumab for treating wet age-related macular degeneration
Brolucizumab 11.08.02 Formulary NICE TA820: Brolucizumab for treating diabetic macular oedema
Budesonide 01.05.02 Formulary NICE TA937: Targeted-release budesonide for treating primary IgA nephropathy
Budesonide orodispersible tablets (Jorveza) 01.05.02 Formulary NICE TA708: Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis
Caffeine citrate 03.05.01 Formulary NICE NG124: Specialist neonatal respiratory care for babies born preterm
Canagliflozin 06.01.02.03 Formulary NICE TA315: Canagliflozin in combination therapy for treating type 2 diabetes
Canagliflozin 06.01.02.03 Formulary NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Cannabidiol 04.08.01 Formulary NICE TA873: Cannabidiol for treating seizures caused by tuberous sclerosis complex
Cannabis extract 10.02.02 Formulary NICE NG144: Cannabis-based medicinal products
Caplacizumab 09.01.04 Formulary NICE TA667: Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura
Carbetocin 07.01.01 Formulary NICE NG235: Intrapartum care
Cenobamate 04.08.01 Formulary NICE TA753: Cenobamate for treating focal onset seizures in epilepsy
Certolizumab Pegol 10.01.03 Formulary NICE TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
Certolizumab Pegol 10.01.03 Formulary NICE TA415: Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor
Certolizumab Pegol 10.01.03 Formulary NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Cetirizine 03.04.01 Formulary NICE advice [ESUOM31]: Chronic urticaria: off-label doses of cetirizine
Ciclosporin 0.1% eye drops 11.11 Formulary NICE TA369: Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears
Cilostazol 02.06.04 Formulary NICE TA223- Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease
Cinacalcet 09.05.01.02 Formulary NICE TA117: Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy
Clomifene Citrate 06.05.01 Formulary NICE CG156: Fertility problems: assessment and treatment
Clonidine Hydrochloride 02.05.02 Formulary NICE NG136: Hypertension in adults: diagnosis and management
Clopidogrel 02.09 Formulary NICE NG185: Acute coronary syndromes
Clopidogrel 02.09 Formulary NICE TA210- Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events
Cyanocobalamin 09.01.02 Formulary NICE NG239: Vitamin B12 deficiency in over 16s: diagnosis and management
Dabigatran 02.08.02 Formulary NICE TA249: Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation
Dabigatran 02.08.02 Formulary NICE TA157: Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults
Dabigatran 02.08.02 Formulary NICE TA327: Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
Dalteparin 02.08.01 Formulary NICE HST28: Birch bark extract for treating epidermolysis bullosa
Dapagliflozin 06.01.02.03 Formulary NICE TA418: Dapagliflozin in triple therapy for treating type 2 diabetes
Dapagliflozin 06.01.02.03 Formulary NICE TA775: Dapagliflozin for treating chronic kidney disease
Dapagliflozin 06.01.02.03 Formulary NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Dapagliflozin 06.01.02.03 Formulary NICE TA288: Dapagliflozin in combination therapy for treating type 2 diabetes
Dapagliflozin 02.05.05 Formulary NICE TA679: Dapagliflozin for treating chronic heart failure with reduced ejection fraction
Dapagliflozin 02.05.05 Formulary NICE TA902: Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction
Daratumumab 08.01.05 Formulary NICE TA959: Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis
Daratumumab 08.01.05 Formulary NICE TA959: Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis
Daridorexant 04.01.01 Formulary NICE TA922: Daridorexant for treating long-term insomnia
Darvadstrocel 01.07.04 Non Formulary NICE TA556: Darvadstrocel for treating complex perianal fistulas in Crohn’s disease
Denosumab 06.06.02 Formulary NICE TA265: Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours
Denosumab 06.06.02 Formulary NICE TA204: Osteoporotic fractures - denosumab
Desmopressin injection 06.05.02 Formulary NICE CG111: Bedwetting in under 19s
Desmopressin tablets and spray 06.05.02 Formulary NICE CG111: Bedwetting in under 19s
Deucravacitinib 13.05.03 Formulary NICE TA907: Deucravacitinib for treating moderate to severe plaque psoriasis
Dexamethasone intravitreal implant 11.04.01 Formulary NICE TA460: Adalimumab and dexamethasone for treating non-infectious uveitis
Dexamethasone intravitreal implant 11.04.01 Formulary NICE TA824: Dexamethasone intravitreal implant for treating diabetic macular oedema
Difelikefalin 13.03 Formulary NICE TA890: Difelikefalin for treating pruritus in people having haemodialysis
Dimethyl Fumarate 13.05.02 Formulary NICE TA475: Dimethyl fumarate for treating moderate to severe plaque psoriasis
Dinoprostone 07.01.01 Formulary NICE NG207: Inducing labour
Dipyridamole 02.09 Formulary NICE NG128: Stroke and transient ischaemic attack in over 16s: diagnosis and initial management
Dipyridamole 02.09 Formulary NICE TA210- Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events
Dronedarone 02.03.02 Formulary NICE TA197: Dronedarone for the treatment of non-permanent atrial fibrillation Link Shared Care Guideline: Amiodarone and Dronedarone
Dupilumab 13.05.03 Formulary NICE TA955: Dupilumab for treating moderate to severe prurigo nodularis
Dupilumab 13.05.03 Formulary NICE TA534: Dupilumab for treating moderate to severe atopic dermatitis
Edoxaban 02.08.02 Formulary NICE TA355: Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation
Edoxaban 02.08.02 Formulary NICE TA354: Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism
Eladocagene exuparvovec 09.08 Formulary NICE: Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiency
Eltrombopag 09.01.04 Formulary NICE TA293: Eltrombopag for treating chronic immune thrombocytopenia
Eltrombopag 09.01.04 Formulary NICE TA382: Eltrombopag for treating severe aplastic anaemia refractory to immunosuppressive therapy (terminated appraisal)
Eluxadoline 01.02 Formulary NICE TA471: Eluxadoline for treating irritable bowel syndrome with diarrhoea
Empagliflozin 06.01.02.03 Formulary NICE TA336: Empagliflozin in combination therapy for treating type 2 diabetes
Empagliflozin 06.01.02.03 Formulary NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Empagliflozin 06.01.02.03 Formulary NICE TA942: Empagliflozin for treating chronic kidney disease
Empagliflozin 02.05.05 Formulary NICE TA773: Empagliflozin for treating chronic heart failure with reduced ejection fraction
Empagliflozin 02.05.05 Formulary NICE TA929: Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction
Enalapril 02.05.05.01 Formulary NG133: Hypertension in pregnancy: diagnosis and management
Enoximone injection 02.01.02 Formulary NICE TA927:Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments
Epcoritamab 08.01.05 Formulary NICE TA954: Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments
Eplerenone 02.02.03 Formulary NG106: Chronic heart failure in adults: diagnosis and management
Erenumab 04.07.04.02 Formulary NICE TA682: Erenumab for preventing migraine
Ertugliflozin 06.01.02.03 Formulary NICE TA572: Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes
Etanercept 10.01.03 Formulary NICE TA199: Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis
Etanercept 10.01.03 Formulary NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Etanercept 10.01.03 Formulary NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Etanercept 10.01.03 Formulary NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Etanercept 10.01.03 Formulary NICE TA715: Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed
Etanercept 10.01.03 Formulary NICE TA195:Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor
Etanercept 13.05.03 Formulary NICE TA103: Etanercept and efalizumab for the treatment of adults with psoriasis
Etanercept 13.05.03 Formulary NICE TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
Etelcalcetide 09.05.01.02 Formulary NICE TA448: Etelcalcetide for treating secondary hyperparathyroidism
Etrasimod 01.05.03 Formulary NICE TA956: Etrasimod for treating moderately to severely active ulcerative colitis in people aged 16 and over
Evolocumab 02.12 Formulary NICE TA394 - Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
Ezetimibe 02.12 Formulary NICE TA385 - Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia
Faricimab 11.08.02 Formulary NICE TA799: Faricimab for treating diabetic macular oedema
Faricimab 11.08.02 Formulary NICE TA800: Faricimab for treating wet age-related macular degeneration
Fenfluramine 04.08.01 Formulary NICE TA808: Fenfluramine for treating seizures associated with Dravet syndrome
Filgotinib 10.01.03 Formulary NICE TA676: Filgotinib for treating moderate to severe rheumatoid arthritis
Filgotinib 01.05.03 Formulary NICE TA792: Filgotinib for treating moderately to severely active ulcerative colitis
Finerenone 02.02.03 Formulary NICE TA877 Finerenone for treating chronic kidney disease in type 2 diabetes
Finerenone 06.01.05 Formulary NICE TA877: Finerenone for treating chronic kidney disease in type 2 diabetes
Fluocinolone intravitreal implant 11.04.01 Formulary NICE TA590: Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis
Fluocinolone intravitreal implant 11.04.01 Formulary NICE TA953: Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema
Fondaparinux 02.08.01 Formulary NICE NG185: Acute coronary syndromes
Foslevodopa–Foscarbidopa 04.09.01 Formulary NICE TA934: Foslevodopa–foscarbidopa for treating advanced Parkinson’s with motor symptoms
Fostamatinib 09.01.04 Formulary NICE TA935: Fostamatinib for treating refractory chronic immune thrombocytopenia
Fremanezumab 04.07.04.02 Formulary NICE TA764: Fremanezumab for preventing migraine
Glibenclamide 06.01.02.01 Formulary Diabetes in pregnancy: management from preconception to the postnatal period
Glycopyrrolate/ indacaterol inhaler 03.01.04 Non Formulary NICE New Medicine Evidence Summary 33: indacaterol/glycopyrronium (Ultibro Breezhaler)
Golimumab 01.05.03 Formulary NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
Golimumab 01.05.03 Formulary NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
Golimumab 10.01.03 Formulary NICE TA497: Golimumab for treating non-radiographic axial spondyloarthritis
Golimumab 10.01.03 Formulary NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Golimumab 10.01.03 Formulary NICE TA220: Golimumab for the treatment of psoriatic arthritis
Golimumab 10.01.03 Formulary NICE TA225: Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs
Golimumab 10.01.03 Formulary NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Guselkumab 10.01.03 Formulary NICE TA815: Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs
Guselkumab 13.05.03 Formulary NICE TA521: Guselkumab for treating moderate to severe plaque psoriasis
Helicobacter pylori eradication 01.03 Formulary NICE NG184: Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management
Holoclar 11.11 Formulary NICE TA467: Holoclar for treating limbal stem cell deficiency after eye burns
Hydralazine 02.05.01 Formulary NG106: Chronic heart failure in adults: diagnosis and management
Icosapent ethyl 02.12 Formulary NICE TA805: Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides
Iloprost injection 02.05.01 Non Formulary NICE: review of evidence
Iloprost nebuliser solution 02.06.04 Formulary NICE TA918:Bimekizumab for treating axial spondyloarthritis
Iloprost nebuliser solution 02.06.04 Formulary NICE TA916: Bimekizumab for treating active psoriatic arthritis
Inclisiran 02.12 Formulary NICE TA733 - Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia
Indapamide 02.02.01 Formulary NG136: Hypertension in adults: diagnosis and management
Infliximab 01.05.03 Formulary NICE TA163: Ulcerative colitis (acute manifestations) Infliximab
Infliximab 01.05.03 Formulary NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262)
Infliximab 01.05.03 Formulary NICE TA187: Crohns disease - infliximab & adalimumab
Infliximab 01.05.03 Formulary NICE TA187: Infliximab and adalimumab for the treatment of Crohn’s disease
Infliximab 01.05.03 Formulary NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
Infliximab 01.05.03 Formulary NICE TA163: Infliximab for acute exacerbations of ulcerative colitis
Infliximab 01.05.03 Formulary NICE TA187: Infliximab and adalimumab for the treatment of Crohn’s disease
Infliximab 01.05.03 Formulary NICE TA163: Infliximab for acute exacerbations of ulcerative colitis
Infliximab 01.05.03 Formulary NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
Infliximab 01.05.03 Formulary NICE TA187: Infliximab and adalimumab for the treatment of Crohn’s disease
Infliximab 01.05.03 Formulary NICE TA163: Infliximab for acute exacerbations of ulcerative colitis
Infliximab 01.05.03 Formulary NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
Infliximab 10.01.03 Formulary NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Infliximab 10.01.03 Formulary NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Infliximab 10.01.03 Formulary NICE TA195:Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor
Infliximab 10.01.03 Formulary NICE TA199: Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis
Infliximab 10.01.03 Formulary NICE TA715: Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed
Infliximab 13.05.03 Formulary NICE TA134: Infliximab for the treatment of adults with psoriasis
Iptacopan 09.01.03 Formulary NICE TA1000: Iptacopan for treating paroxysmal nocturnal haemoglobinuria
Ivabradine 02.06.03 Formulary NICE TA267: Ivabradine for treating chronic heart failure
Ivabradine 02.06.03 Formulary NICE: Stable angina: management
Ivacaftor–Tezacaftor–Elexacaftor 03.07 Formulary NICE TA988: Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis
Ivermectin cream 1% 13.06 Formulary NICE: Inflammatory lesions of papulopustular rosacea: ivermectin 10 mg/g cream
Ixekizumab 13.05.02 Formulary NICE TA442: Ixekizumab for treating moderate to severe plaque psoriasis
Ixekizumab 13.05.02 Formulary NICE TA537: Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs
Ixekizumab 10.01.03 Formulary NICE TA537: Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs
Ixekizumab 10.01.03 Formulary NICE TA718: Ixekizumab for treating axial spondyloarthritis
Labetalol 02.04 Formulary NICE: Hypertension in pregnancy: diagnosis and management
Lanadelumab 03.04.03 Formulary NICE TA606: Lanadelumab for preventing recurrent attacks of hereditary angioedema
Lebrikizumab 13.05.03 Formulary NICE TA986: Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over
Linaclotide 01.06.07 Formulary NICE CG61: Irritable bowel syndrome in adults: diagnosis and management
Liraglutide 04.05.01 Formulary NICE TA664: Liraglutide for managing overweight and obesity
Liraglutide  06.01.02.03 Formulary NICE TA664: Liraglutide for managing overweight and obesity
Loperamide 01.04.02 Formulary NICE: Short bowel syndrome
Lubiprostone 01.06.07 Formulary NICE TA318: Lubiprostone for treating chronic idiopathic constipation
Lumacaftor/Ivacaftor 03.07 Non Formulary NICE TA398: Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation
Lumacaftor–Ivacaftor 03.07 Formulary NICE TA988: Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis
Lumasiran 10.01.04 Formulary NICE: Lumasiran for treating primary hyperoxaluria type 1
Lusutrombopag 09.01.04 Formulary NICE TA617: Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure
Magnesium Glycerophosphate 09.05.01.03 Formulary NICE: Preventing recurrent hypomagnesaemia: oral magnesium glycerophosphate
Mannitol 03.07 Formulary NICE TA266: Mannitol dry powder for inhalation for treating cystic fibrosis
Mepolizumab 03.04.02 Formulary NICE TA671: Mepolizumab for treating severe eosinophilic asthma
Metformin 06.01.02.02 Formulary NICE: Type 2 diabetes: prevention in people at high risk
Methyldopa 02.05.02 Formulary NG133: Hypertension in pregnancy: diagnosis and management
Methylprednisolone 06.03.02 Formulary NICE: Multiple Sclerosis; management in primary and secondary care.
Metolazone 02.02.01 Formulary NICE TA932: Decitabine–cedazuridine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (terminated appraisal)
Mexiletine hydrochloride 10.02.02 Formulary NICE TA748: Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders
Mifepristone 07.01.02 Formulary NICE NG140: Abortion care
Mirabegron 07.04.02 Formulary NICE TA290: Mirabegron for treating symptoms of overactive bladder
Mirikizumab 01.05.03 Formulary NICE TA925: Mirikizumab for treating moderately to severely active ulcerative colitis
Misoprostol 07.01.01 Formulary NICE NG140: Abortion care
Momelotinib 08.01.05 Formulary NICE TA957: Momelotinib for treating myelofibrosis-related splenomegaly or symptoms
Naftidrofuryl oxalate 02.06.04 Formulary NICE TA223- Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease
Naldemedine tosylate 01.06.06 Formulary NICE TA651: Naldemedine for treating opioid-induced constipation
Naloxegol 01.06.06 Formulary NICE TA345: Naloxegol for treating opioid‑induced constipation
Naltrexone 04.10.03 Formulary NICE TA115: Naltrexone for the management of opioid dependence
Nicorandil 02.06.03 Formulary NICE: Stable angina: management
Nifedipine 02.06.04 Formulary NICE NG133: Hypertension in pregnancy: diagnosis and management
Nintedanib 03.11 Formulary NICE TA379: Nintedanib for treating idiopathic pulmonary fibrosis
Nintedanib 03.11 Formulary NICE TA864 Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted
Nintedanib 03.11 Formulary NICE TA747: Nintedanib for treating progressive fibrosing interstitial lung diseases
Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab 05.03 Formulary NICE TA878: Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19
Nusinersen 10.02 Formulary NICE TA588: Nusinersen for treating spinal muscular atrophy
Obeticholic acid 01.09.01 Formulary NICE TA443: Obeticholic acid for treating primary biliary cholangitis
Ocrelizumab 08.02.03 Formulary NICE TA585: Ocrelizumab for treating primary progressive multiple sclerosis
Ocrelizumab 08.02.03 Formulary NICE TA533: Ocrelizumab for treating relapsing–remitting multiple sclerosis
Omalizumab 03.04.02 Formulary NICE TA678: Omalizumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal)
Omalizumab 03.04.02 Formulary NICE TA278: Omalizumab for treating severe persistent allergic asthma
Omega-3-Acid Ethyl Esters 02.12 Non Formulary NICE: schizophrenia - omega-3 fatty acid medicines
Omega-3-Marine Triglycerides 02.12 Non Formulary NICE: schizophrenia - omega-3 fatty acid medicines
Onasemnogene abeparvovec 10.02 Formulary NICE: Onasemnogene abeparvovec for treating spinal muscular atrophy
Onasemnogene abeparvovec 10.02 Formulary NICE: Onasemnogene abeparvovec for treating presymptomatic spinal muscular atrophy
Ondansetron 04.06 Formulary NICE: Management of vomiting in children and young people with gastroenteritis: ondansetron
Ozanimod 01.05.03 Formulary NICE TA828: Ozanimod for treating moderately to severely active ulcerative colitis
Palforzia 03.04.02 Formulary NICE TA769: Palforzia for treating peanut allergy in children and young people
Parathyroid Hormone 06.06.01 Non Formulary NICE TA625: Recombinant human parathyroid hormone for treating hypoparathyroidism (terminated appraisal)
Patiromer calcium 09.02.01.01 Formulary NICE TA623: Patiromer for treating hyperkalaemia
Pegunigalsidase alfa 09.08.01 Formulary NICE TA915: Pegunigalsidase alfa for treating Fabry disease
Pentosan polysulfate sodium 07.04.03 Formulary NICE TA610: Pentosan polysulfate sodium for treating bladder pain syndrome
Pentoxifylline 02.06.04 Formulary NICE TA223- Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease
Perampanel 04.08.01 Formulary NICE NG217: Epilepsies in children, young people and adults
Pimecrolimus 1% 13.05.03 Formulary NICE TA82: Tacrolimus and pimecrolimus for atopic eczema
Pirfenidone 03.11 Formulary NICE TA504: Pirfenidone for treating idiopathic pulmonary fibrosis
Prasugrel 02.09 Formulary NICE TA317- Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes
Progestogen (micronised) vaginal capsules 06.04.01.02 Formulary NICE NG126: Ectopic pregnancy and miscarriage: diagnosis and initial management
Promethazine 03.04.01 Formulary NICE Evidence Summary: Rapid tranquillisation in mental health settings: promethazine hydrochloride
Propafenone 02.03.02 Formulary NICE TA934:Foslevodopa–foscarbidopa for treating advanced Parkinson’s with motor symptoms
Prucalopride 01.06.07 Formulary NICE TA211: Prucalopride for the treatment of chronic constipation in women
Raloxifene Hydrochloride 06.04.01.01 Formulary NICE TA160: Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women
Raloxifene Hydrochloride 06.04.01.01 Formulary NICE TA161:Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women
Ranibizumab 11.08.02 Formulary NICE TA274: Ranibizumab for treating diabetic macular oedema
Ranibizumab 11.08.02 Formulary NICE TA637: Ranibizumab for treating diabetic retinopathy (terminated appraisal)
Ravulizumab 09.01.03 Formulary NICE TA710: Ravulizumab for treating atypical haemolytic uraemic syndrome
Ravulizumab 09.01.03 Formulary NICE TA698: Ravulizumab for treating paroxysmal nocturnal haemoglobinuria
Relugolix–estradiol–norethisterone acetate 06.07.02 Formulary NICE TA832: Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroids
Reslizumab 03.04.02 Formulary NICE TA479: Reslizumab for treating severe eosinophilic asthma
Riluzole 04.09.03 Formulary NICE TA20: Guidance on the use of riluzole (Rilutek) for the treatment of motor neurone disease
Rimegepant 04.06 Formulary NICE TA906: Rimegepant for preventing migraine
Risankizumab 13.05.03 Formulary NICE TA596: Risankizumab for treating moderate to severe plaque psoriasis
Risankizumab 13.05.03 Formulary NICE TA803: Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs
Risankizumab 10.01.03 Formulary NICE TA803: Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs
Risankizumab 01.05.03 Formulary NICE TA888: Risankizumab for previously treated moderately to severely active Crohn’s disease
Risdiplam 10.02 Formulary NICE TA755: Risdiplam for treating spinal muscular atrophy
Rituximab (rheumatology) 10.01.03 Formulary NICE TA195:Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor
Rivaroxaban 02.08.02 Formulary NICE TA256: Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation
Rivaroxaban 02.08.02 Formulary NICE TA170: Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults
Rivaroxaban 02.08.02 Formulary NICE TA335: Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome
Rivaroxaban 02.08.02 Formulary NICE TA287: Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism
Rivaroxaban 02.08.02 Formulary NICE TA261: Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism
Rivaroxaban with aspirin 02.08.02 Formulary NICE TA607: Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease
Rivaroxaban with aspirin 02.08.02 Formulary NICE TA:919 Rimegepant for treating migraine
Roflumilast 03.03.03 Formulary NICE TA461: Roflumilast for treating chronic obstructive pulmonary disease
Roflumilast 03.03.03 Formulary NICE TA 244: Chronic obstructive pulmonary disease - roflumilast (only as part of a trial)
Romiplostim 09.01.04 Formulary NICE TA221: Romiplostim for the treatment of chronic immune thrombocytopenia
Romosozumab 06.06.02 Formulary NICE TA791: Romosozumab for treating severe osteoporosis
Roxadustat 09.01.01 Formulary NICE TA807: Roxadustat for treating symptomatic anaemia in chronic kidney disease
Sacubitril/valsartan 02.05.05.02 Formulary NICE TA388 Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction
Sarilumab 10.01.03 Formulary NICE TA485: Sarilumab for moderate to severe rheumatoid arthritis
Secukinumab 13.05.03 Formulary NICE TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
Secukinumab 13.05.03 Formulary NICE TA734: Secukinumab for treating moderate to severe plaque psoriasis in children and young people
Secukinumab 13.05.03 Formulary NICE TA350: Secukinumab for treating moderate to severe plaque psoriasis
Secukinumab 10.01.03 Formulary NICE TA719: Secukinumab for treating non-radiographic axial spondyloarthritis
Secukinumab 10.01.03 Formulary NICE TA407: Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors
Secukinumab 10.01.03 Formulary NICE TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
Semaglutide 06.01.02.03 Formulary NICE TA875: Semaglutide for managing overweight and obesity
Semaglutide 04.05.01 Formulary NICE TA875: Semaglutide for managing overweight and obesity
Setmelanotide 06.07 Formulary NICE HST21: Setmelanotide for treating obesity caused by LEPR or POMC deficiency
Setmelanotide 06.07 Formulary NICE HST31: Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome
Sildenafil 02.06.04 Formulary NICE ESOUM42: Digital ulcers: sildenafil
Sildenafil 02.06.04 Formulary NICE: Digital ulcers: sildenafil
Simvastatin and Ezetimibe Inegy 02.12 Formulary NICE TA 915:Pegunigalsidase alfa for treating Fabry diease
Sodium zirconium cyclosilicate 09.02.01.01 Formulary NICE TA599: Sodium zirconium cyclosilicate for treating hyperkalaemia
Solriamfetol hydrochloride 04.04 Formulary NICE TA758: Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy
Somatrogon 06.05.01 Formulary NICE TA863 Somatrogon for treating growth disturbance in children and young people aged 3 years and over
Somatropin 06.05.01 Formulary NICE TA64: Human growth hormone (somatropin) in adults with growth hormone deficiency
Somatropin 06.05.01 Formulary NICE TA188: Human growth hormone (somatropin) for the treatment of growth failure in children
Somatropin 06.05.01 Formulary NICE TA64: Growth hormone deficiency (adults)
Somatropin 06.05.01 Formulary NICE TA188: Human growth hormone (somatropin) for the treatment of growth failure in children
Spironolactone 02.02.03 Formulary NG106: Chronic heart failure in adults: diagnosis and management
Streptokinase 02.10.02 Formulary NICE TA52: Guidance on the use of drugs for early thrombolysis in the treatment of acute myocardial infarction
Tacrolimus 13.05.03 Formulary NICE TA82: Tacrolimus and pimecrolimus for atopic eczema
Tadalafil 07.04.05 Formulary NICE TA273: Tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia (terminated appraisal)
Tafamidis 16.01 Formulary NICE TA984: Tafamidis for treating transthyretin amyloidosis with cardiomyopathy
Teduglutide 01.04.02 Formulary NICE TA804: Teduglutide for treating short bowel syndrome
Tenecteplase 02.10.02 Formulary NICE TA52- Guidance on the use of drugs for early thrombolysis in the treatment of acute myocardial infarction
Teriparatide 06.06.01 Formulary NICE TA161: Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women
Terlipressin 06.05.02 Formulary NICE CG141: Acute upper gastrointestinal bleeding in over 16s: management
Tezacaftor–Ivacaftor 03.07 Formulary NICE TA988: Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis
Tezepelumab 03.04.02 Formulary NICE TA880 Tezepelumab for treating severe asthma
Theophylline 03.01.03 Formulary BNF: Theophylline
Ticagrelor 02.09 Formulary NICE TA420 - Ticagrelor for preventing atherothrombotic events after myocardial infarction
Ticagrelor 02.09 Formulary NICE NG185: Acute coronary syndromes
Ticagrelor 02.09 Formulary NICE TA236 - Ticagrelor for the treatment of acute coronary syndromes
Tildrakizumab 13.05.03 Formulary NICE TA575: Tildrakizumab for treating moderate to severe plaque psoriasis
Tirzepatide 06.01.02.03 Formulary NICE TA924: Tirzepatide for treating type 2 diabetes
Tocilizumab 10.01.03 Formulary NICE TA518: Tocilizumab for treating giant cell arteritis
Tocilizumab 10.01.03 Formulary NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Tocilizumab 10.01.03 Formulary NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Tofacitinib 01.05.03 Formulary NICE TA547: Tofacitinib for moderately to severely active ulcerative colitis
Tofacitinib 10.01.03 Formulary NICE TA735: Tofacitinib for treating juvenile idiopathic arthritis
Tofacitinib 10.01.03 Formulary NICE TA920: Tofacitinib for treating active ankylosing spondylitis
Tofacitinib 10.01.03 Formulary NICE TA543: Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs
Tofacitinib 10.01.03 Formulary NICE TA547: Tofacitinib for moderately to severely active ulcerative colitis
Tofacitinib 10.01.03 Formulary NICE TA480: Tofacitinib for moderate to severe rheumatoid arthritis
Tolvaptan 06.05.02 Formulary NICE TA358 Tolvaptan for treating autosomal dominant polycystic kidney disease
Tralokinumab 13.05.03 Formulary NICE TA814: Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis
Tranexamic Acid 02.11 Formulary NICE NG39: Major trauma: assessment and initial management
Upadacitinib 01.05.03 Formulary NICE TA856: Upadacitinib for treating moderately to severely active ulcerative colitis
Upadacitinib 01.05.03 Formulary NICE TA905: Upadacitinib for previously treated moderately to severely active Crohn’s disease
Upadacitinib 10.01.03 Formulary NICE TA665: Upadacitinib for treating severe rheumatoid arthritis
Upadacitinib 10.01.03 Formulary NICE TA744: Upadacitinib for treating moderate rheumatoid arthritis
Upadacitinib 10.01.03 Formulary NICE TA768: Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs
Upadacitinib 10.01.03 Formulary NICE TA829: Upadacitinib for treating active ankylosing spondylitis
Upadacitinib 10.01.03 Formulary NICE TA861: Upadacitinib for treating active non-radiographic axial spondyloarthritis
Upadacitinib 13.05.03 Formulary NICE768: Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs
Upadacitinib 13.05.03 Formulary NICE TA814: Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis
Ustekinumab 01.05.03 Formulary NICE TA633: Ustekinumab for treating moderately to severely active ulcerative colitis
Ustekinumab 01.05.03 Formulary NICE TA456: Ustekinumab for moderately to severely active Crohn’s disease after previous treatment
Ustekinumab 13.05.03 Formulary NICE TA180: Ustekinumab for the treatment of adults with moderate to severe psoriasis
Ustekinumab 13.05.03 Formulary NICE TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
Ustekinumab 01.05.03 Formulary NICE TA456: Ustekinumab for moderately to severely active Crohn’s disease after previous treatment
Ustekinumab 01.05.03 Formulary NICE TA633: Ustekinumab for treating moderately to severely active ulcerative colitis
Ustekinumab 10.01.03 Formulary NICE TA340: Ustekinumab for treating active psoriatic arthritis
Varenicline 04.10.02 Formulary NICE TA123: Varenicline for smoking cessation
Vedolizumab 01.05.03 Formulary NICE TA342: Vedolizumab for treating moderately to severely active ulcerative colitis
Vedolizumab 01.05.03 Formulary NICE TA352: Vedolizumab for treating moderately to severely active Crohn’s disease after prior therapy
Vericiguat 02.05 Non Formulary NICE TA731:Vericiguat for treating chronic heart failure with reduced ejection fraction (terminated appraisal)
Vernakalant 02.03.02 Non Formulary NICE TA675: Vernakalant for the rapid conversion of recent onset atrial fibrillation to sinus rhythm (terminated appraisal)
Volanesorsen 02.12 Formulary NICE HST13: Volanesorsen for treating familial chylomicronaemia syndrome
Voretigene neparvovex 11.11 Formulary NICE: Voretigene neparvovec for treating inherited retinal dystrophies caused by RPE65 gene mutations
Vortioxetine 04.03.03 Formulary NICE TA367: Vortioxetine for treating major depressive episodes
Voxelotor 09.01.03 Formulary NICE TA981: Voxelotor for treating haemolytic anaemia caused by sickle cell disease
Vutrisiran 09.08.01 Formulary NICE TA868: Vutrisiran for treating hereditary transthyretin-related amyloidosis
Lancashire and South Cumbria